William Anderson - Roche Holding CEO
| RHHBF Stock | USD 318.44 15.52 5.12% |
CEO
Mr. William N. Anderson was Member of the Corporationrationrate Executive Committee, Chief Executive Officer Roche Pharmaceuticals at Roche Holding Ltd since January 1, 2019. He is former Chief Executive Officer of Genentech. since 2019.
| Age | 57 |
| Tenure | 5 years |
| Phone | 41 61 688 11 11 |
| Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | CEO Age | ||
| Brian McNamara | GlaxoSmithKline PLC ADR | 49 | |
| Emma Walmsley | GlaxoSmithKline PLC ADR | 55 | |
| Severin Schwan | Roche Holding Ltd | 56 | |
| Severin Schwan | Roche Holding AG | 56 | |
| Jose Buenache | Grifols SA ADR | 56 | |
| Richard Saynor | Novartis AG ADR | 57 | |
| Pascal Soriot | AstraZeneca PLC ADR | 60 | |
| Nacho Abia | Grifols SA ADR | 56 | |
| Deborah Waterhouse | GlaxoSmithKline PLC ADR | N/A | |
Management Performance
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 |
Roche Holding AG Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Schadler, Head Communications | ||
| Claudia Bockstiegel, G Counsel | ||
| Bruno Eschli, Head Relations | ||
| Johannes MD, Head Devel | ||
| Thomas Schinecker, Chief Diagnostics | ||
| Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
| William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
| Alan Hippe, CFO and IT Officer | ||
| Severin Schwan, CEO and Director | ||
| Pascale Schmidt, Chief Officer |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 287.91 B | |||
| Shares Outstanding | 106.69 M | |||
| Shares Owned By Insiders | 75.31 % | |||
| Shares Owned By Institutions | 8.56 % | |||
| Price To Earning | 21.63 X | |||
| Price To Book | 11.61 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Roche OTC Stock
Roche Holding financial ratios help investors to determine whether Roche OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Roche with respect to the benefits of owning Roche Holding security.